Introduction {#Sec1}
============

Several authorities have called attention to the morbidity, mortality and excess health costs associated with antibiotic-resistant pathogens and the need to prioritize development of antibacterial agents that can safely and effectively treat these pathogens \[[@CR1]--[@CR4]\]. Ceftaroline fosamil is a novel cephalosporin, with bactericidal in vitro activity against pathogens associated with licensed indications, including resistant organisms, such as methicillin-resistant *Staphylococcus aureus* (MRSA), multidrug-resistant *Streptococcus pneumoniae* (MDRSP) and penicillin-resistant *S. pneumoniae* (PRSP) \[[@CR5]\]. Supported by preclinical in vitro and animal model studies \[[@CR6]--[@CR10]\] and clinical trials \[[@CR11]--[@CR15]\], ceftaroline fosamil (Teflaro™; Forest Laboratories, Inc., New York, USA) was approved by the United States Food and Drug Administration (FDA) in October 2010 for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible organisms \[[@CR5]\]. Ceftaroline fosamil is the newest of only three systemic antibiotics approved for human use by the FDA over the past 5 years and the only one of these approved for the treatment of CABP. Similarly, the European Commission granted marketing authorization for ceftaroline fosamil (Zinforo™; AstraZeneca, Södertälje, Sweden) in August 2012 for the treatment of community-acquired pneumonia and complicated skin and soft tissue infections following favorable opinion from the Committee for Medicinal Products for Human Use \[[@CR16]\]. This report reviews the recent literature published on ceftaroline fosamil, including the pivotal clinical trials that led to its approval, and highlights areas that need to be addressed in the future.

Mechanism of action and spectrum of activity {#Sec2}
============================================

Similar to other β-lactam antibiotics, ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, mediates its bactericidal effect by binding to membrane-bound enzymes known as penicillin-binding proteins (PBPs), thereby interfering with bacterial cell wall synthesis and leading to cell lysis and death \[[@CR17]\]. Distinguishing it from other β-lactam antibiotics, however, is its unique high binding affinity for PBP 2a (which confers resistance to MRSA) and PBP 2b, 2x and 1a (which confer resistance to PRSP) \[[@CR18], [@CR19]\]. The favorable activity of ceftaroline against clinical isolates, including potent activity against Gram-positive bacteria, such as MRSA, vancomycin-intermediate *S. aureus* (VISA) and PRSP, has been demonstrated in isolates collected worldwide \[[@CR20]\] with corroboration from a number of in vitro and in vivo studies \[[@CR6], [@CR10], [@CR21]--[@CR26]\], and maintained during in vitro attempts to generate resistant strains \[[@CR27], [@CR28]\]. Activity against *Enterococcus faecalis* and *Enterococcus faecium* is limited \[[@CR6], [@CR20]\]. Ceftaroline's spectrum of activity against Gram-negative bacteria is comparable to that of many other cephalosporins, and it has no activity against extended-spectrum β-lactamase (ESBL) and carbapenemase-producing strains (e.g., *Klebsiella pneumonia* carbapenemase) or strains with stable de-repressed AmpC β-lactamase production \[[@CR20], [@CR27], [@CR29]\]. In vitro activity against Gram-positive anaerobes is similar to that of amoxicillin--clavulanate, with good activity against *Propionibacterium* spp. and *Actinomyces* spp. \[[@CR30], [@CR31]\]. Ceftaroline is inactive against most β-lactamase-producing Gram-negative anaerobes, including *Bacteroides fragilis* and *Prevotella* spp. \[[@CR30], [@CR31]\].

Ceftaroline minimal inhibitory concentrations (MICs) and disk diffusion breakpoints have been defined by the FDA, and more recently by the Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (Table [1](#Tab1){ref-type="table"}) \[[@CR5], [@CR32], [@CR33]\]. Due to the scarcity of resistant Gram-positive isolates at the time of licensing, only susceptible interpretations for Gram-positive strains are available from the FDA \[[@CR5]\]. Target attainment analysis using Monte Carlo simulations support the FDA susceptible interpretative criteria for *S. aureus* (MIC ≤1 μg/mL) when the recommended ceftaroline fosamil dosing regimen is used \[[@CR34]\]. In vivo murine thigh infection models suggest that human simulated exposures of ceftaroline 600 mg every 12 h may have efficacy in the treatment of *S. aureus* infections with MICs as high as 4 μg/mL \[[@CR35]\], but more data on clinical outcomes associated with higher ceftaroline MICs are needed.Table 1Food and Drug Administration (FDA), Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive minimum inhibitory concentration breakpoints (μg/mL) for ceftaroline \[[@CR5], [@CR32], [@CR33]\]OrganismFDA^a^CLSIEUCASTSIRSIRSR*Staphylococcus* *aureus* ^b^≤1----≤12≥4≤1\>1*Streptococcus* *pneumoniae*≤0.25----≤0.5^c^----≤0.25\>0.25*Streptococcus* *agalactiae*≤0.03----≤0.5^dd^*Streptococcus* *pyogenes*≤0.015----≤0.5----^dd^*Haemophilus* *influenzae*≤0.12----≤0.5----≤0.03\>0.03Enterobacteriaceae≤0.51≥2≤0.51≥2≤0.5\>0.5*I* intermediate, *R* resistant, *S* susceptible^a^Intermediate and resistant results not defined by the FDA for some pathogens^b^Includes methicillin-resistant *S. aureus*^c^Non-meningitis^d^β-Lactam susceptibility of *Streptococcus* groups A, B, C and G is inferred from the penicillin susceptibility

Results from the 2010 Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) program (Table [2](#Tab2){ref-type="table"}) \[[@CR36]--[@CR42]\], a global ceftaroline surveillance study, showed that ceftaroline is highly active against *S. aureus* and MRSA among isolates collected from medical centers in nine United States census regions \[[@CR36]\]. These high rates of *S. aureus* susceptibility were independent of patient age group \[[@CR36]\]. Among respiratory pathogens, 98.7% of *S. pneumoniae* strains were inhibited by 0.25 μg/mL or less of ceftaroline, exhibiting potency 16 times greater than that of ceftriaxone \[[@CR37]\]. During 2008--2010, there was sustained potency and activity against MRSA and MDRSP \[defined as a *S. pneumoniae* isolate with resistance to at least two of the following antimicrobial agents: penicillin (≥8 μg/mL), ceftriaxone, erythromycin, tetracycline, levofloxacin, and trimethoprim--sulfamethoxazole) and the frequency of non-susceptibility of respiratory pathogens to ceftaroline did not vary significantly \[[@CR37], [@CR38]\]. Geographic differences in activity among staphylococci, streptococci, *Haemophilus* spp., and *Moraxella catarrhalis* were minimal \[[@CR39]\]. Susceptibility patterns to ceftaroline among MRSA isolates from Europe, South Africa and the Asia--Pacific region were lower than those seen in the USA, while consistently high rates of susceptibility to ceftaroline by methicillin-susceptible *S.* *aureus*, *S.* *pneumoniae*, *Haemophilus* *influenzae* and *M.* *catarrhalis* were maintained across all these regions \[[@CR40]--[@CR42]\]. Ongoing surveillance will be critical to determine whether resistant strains emerge from selective pressure elicited by more widespread use of ceftaroline. High rates of intermediate susceptibility of *S. aureus* to ceftaroline have already been noted in vitro among isolates from a surveillance program in China; 36.2% of the 315 isolates tested had an MIC above 1 μg/mL, although the highest MIC documented was 2 μg/mL \[[@CR43]\].Table 2Summary of ceftaroline activity tested against bacterial isolates causing skin and soft tissue infections and community-acquired pneumonia, by region (AWARE Surveillance, 2010) \[[@CR36]-[@CR42]\]**OrganismMSSAMRSAGASGBSPNEUMPRSP*H. flu**E. coli*United States**No. isolates \[Ref\]1,072 \[[@CR36]\]1,071 \[[@CR38]\]^a^422 \[[@CR39]\]576 \[[@CR39]\]3,329 \[[@CR37]\]^a^1,198 \[[@CR38]\]1,545 \[[@CR37]\]^a^657 \[[@CR39]\]MIC 500.250.5NSNS0.0150.12-0.25≤0.008≤0.06-0.12MIC 900.251≤0.008-015≤0.015-0.030.120.25-0.50.015NS% susceptible^b^100/10098.4/98.497.8-100^c^80.9-93.1^c^98.7^c^NS99.9^c^70.3-92.3^c^**Europe**No. isolates \[Ref\]1092 \[[@CR42]\]331 \[[@CR42]\]460 \[[@CR42]\]^d^799 \[[@CR40]\]130 \[[@CR40]\]515 \[[@CR40]\]323 \[[@CR42]\]MIC 500.251≤0.008≤0.0080.12≤0.0080.25MIC 900.2520.0150.120.250.015\>32% susceptible^b^100/10088.8/88.8100/100100/99.9100/99.2100/97.763.5/63.5**South Africa and Asia-Pacific**No. isolates \[Ref\]413 \[[@CR41]\]211 \[[@CR41]\]113 \[[@CR41]\]^d^616 \[[@CR41]\]202 \[[@CR41]\]453 \[[@CR41]\]137 \[[@CR41]\]MIC 500.251≤0.0080.0150.12≤0.008\>32MIC 900.2520.0150.250.50.03\>32% susceptible^b^100/10080.6/80.6100/10099.8/95.999.5/87.6100/93.432.1/32.1GAS, *S. pyogenes*; GBS, *S. agalactiae*; *H. flu*, *Haemophilus influenzae*; MIC 50, minimum inhibitory concentration that inhibits 50% of bacterial isolates; MIC 90, minimum inhibitory concentration that inhibits 90% of bacterial isolates; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *S.* *aureus*; NS, not stated; PNEUM*, Streptococcus pneumoniae*; PRSP, penicillin-resistant *S. pneumoniae*^a^Surveillance period 2008--2010^b^CLSI, Clinical Laboratory Standards Institute/EUCAST, European Committee on Antimicrobial Susceptibility Testing^c^CLSI only, range dependent on geographic region of the USA^d^β-Hemolytic streptococci

Dose and Administration {#Sec3}
=======================

Following administration, the water-soluble prodrug, ceftaroline fosamil, is rapidly dephosphorylated to the active form in plasma \[[@CR17]\]. For adults 18 years and older, the recommended dose is 600 mg administered intravenously (IV) over 1 h every 12 h. A treatment duration of 5--7 days for CABP and 5--14 days for ABSSSI is currently recommended, guided by the severity of infection and clinical response \[[@CR5]\]. As with other β-lactam antibiotics, time above the MIC is the pharmacodynamic (PD) index that correlates best with efficacy \[[@CR5]\]. Pharmacokinetic (PK) data in healthy adults with normal renal function following multiple doses administered every 12 h over 14 days show that the elimination half-life is about 2.7 h, the maximum observed concentration (*C*~max~) is 21 μg/mL and the area under the concentration--time curve is 56 μg h/mL, with no appreciable accumulation \[[@CR5]\]. Ceftaroline is primarily renally excreted and dosage adjustment is recommended for patients with creatinine clearance (CR~CL~) ≤50 mL/min. For patients with moderate renal impairment (CR~CL~ \>30 to ≤50 mL/min), the dose should be adjusted to 400 mg IV every 12 h. For those with severe renal impairment (CR~CL~ ≥15 to ≤30 mL/min), the dose should be adjusted to 300 mg IV every 12 h and for patients with end-stage renal disease, including those receiving hemodialysis, adjustment to 200 mg IV every 12 h after dialysis should be made \[[@CR5]\].

Following a single IV radiolabeled dose, approximately 88% of radioactivity was recovered in urine and 6% in feces within 48 h \[[@CR5]\]. Of the radioactivity recovered in urine, 64% was excreted as ceftaroline and approximately 2% as the microbiologically inactive ceftaroline M-1 metabolite, suggesting complete transformation of the prodrug \[[@CR5]\]. Ceftaroline is primarily distributed in extracellular fluid and binding to plasma proteins is relatively low (approximately 20%) \[[@CR5]\]. In vitro studies demonstrate that ceftaroline is not a substrate for the cytochrome P450 system and it does not inhibit or induce the major cytochrome P450 isoenzymes. Therefore, there is minimal potential for drug--drug interactions between ceftaroline and drugs that are cytochrome P450 substrates, inhibitors, or inducers \[[@CR5]\].

Clinical Efficacy {#Sec4}
=================

The FOCUS Trials {#Sec5}
----------------

The FOCUS (ceFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalized patients) 1 and 2 studies (NCT00621504 and NCT00509106, respectively) were multinational, multicenter, phase 3, double-masked, randomized, active comparator-controlled trials, designed to evaluate the safety and efficacy of ceftaroline fosamil 600 mg IV every 12 h compared with ceftriaxone 1 g IV every 24 h for 5--7 days for the treatment of typical CABP in patients requiring hospital admission \[[@CR12], [@CR13], [@CR44], [@CR45]\]. Renal dose adjustments were based on creatinine clearance. For subjects enrolled in FOCUS 1 (which included North American participants), clarithromycin was administered during the first 24 h based on established practice guidelines advocating empiric macrolide use \[[@CR46]\].

The primary objective of the studies was to determine whether the clinical cure rate of ceftaroline fosamil was non-inferior to that of ceftriaxone in the co-primary modified intent-to-treat efficacy (MITTE) and clinically evaluable (CE) populations at the test-of-cure (TOC) visit (8--15 days after completion of therapy). The non-inferiority margin was set at −10%. The MITTE population included all participants in the pneumonia risk category (PORT) III or IV who received any amount of study drug according to their randomized treatment group. The CE population included participants in the MITTE population who demonstrated sufficient adherence to the protocol. Baseline characteristics and demographics were comparable between the two study arms and between the two studies. The majority of participants were Caucasian males over the age of 50 years recruited from Eastern and Western Europe. The most common pathogens isolated were *S. pneumoniae* (41.7%) and *S. aureus* (16.5%), followed by Gram-negative organisms, of which *H. influenzae* was the most frequent \[[@CR44]\].

Clinical cure rates favored ceftaroline in a priori-defined integrated analysis of the MITTE and CE populations (Table [3](#Tab3){ref-type="table"}) \[[@CR12]--[@CR15], [@CR44], [@CR47]\]. Planned secondary analysis of the CE subjects with at least one typical pathogen identified at baseline showed clinical cure in 85.1% of participants compared with 75.5% of participants in the ceftaroline and ceftriaxone groups, respectively \[difference 9.7%, 95% confidence interval (CI) 0.7--18.8%\] \[[@CR44]\]. Cure rates against *S. pneumoniae*, MDRSP and *S. aureus* favored ceftaroline, and were similar to ceftriaxone for Gram-negative pathogens \[[@CR44]\]. The efficacy of ceftaroline against MRSA could not be evaluated as patients with suspected MRSA infection were excluded from enrollment (due to a lack of activity of ceftriaxone against MRSA). For bacteremia, cure rates were 71.4% (15 of 21 subjects) compared with 58.8% (10 of 17 subjects) for the ceftaroline and ceftriaxone groups, respectively (difference 12.6%, 95% CI −17.6% to 41.6%) \[[@CR44]\]. At the late follow-up visit (21--35 days after completion of therapy), relapse rates between the two treatment arms were similar in the CE population: 1.9% for the ceftaroline group and 1.2% for the ceftriaxone group (difference 0.7%, 95% CI −1.4% to 2.9%) \[[@CR44]\]. Pooled post hoc exploratory analysis requested by the FDA to assess clinical improvement on day 4 of study therapy in participants with a confirmed bacterial pathogen at baseline showed a weighted difference in clinical response of 11.4% (95% CI 0.6--21.9%) in favor of ceftaroline \[[@CR48]\].Table 3Summary of clinical cure rate at the test-of-cure visit in the co-primary analysis populations, FOCUS and CANVAS trials \[[@CR12]--[@CR15], [@CR44], [@CR47]\]TrialMITTECEFOCUS^a^Clinical cure % (no. of cured/total no.)Difference^b^ (95% CI)Clinical cure % (no. of cured/total no.)Difference^b^ (95% CI)CeftarolineCeftriaxoneCeftarolineCeftriaxone183.8 (244/291)77.7 (233/300)6.2 (−0.2, 12.6)86.6 (194/224)78.2 (183/234)8.4 (1.4, 15.4)281.3 (235/289)75.5 (206/273)5.9 (−1.0, 12.7)82.1 (193/235)77.2 (166/215)4.9 (−2.5, 12.5)1 and 282.6 (479/580)76.6 (439/573)6.0^c^ (1.4, 10.7)84.3 (387/459)77.7 (349/449)6.7^c^ (1.6, 11.8)TrialMITTCECANVAS^a^Clinical cure % (no. cured/total no.)Difference^b^ (95% CI)Clinical cure % (no. cured/total no.)Difference^b^ (95% CI)CeftarolineVanc/AzCeftarolineVanc/Az186.6 (304/351)85.6 (297/347)1.0 (−4.2, 6.2)91.1 (288/316)93.3 (280/300)−2.2 (−6.6, 2.1)285.1 (291/342)85.5 (289/338)−0.4 (−5.8, 5.0)92.2 (271/294))92.1 (269/292)0.1 (−4.4, 4.5)1 and 285.9 (595/693)85.5 (586/685)0.3 (−3.4, 4.0)91.6 (559/610)92.7 (549/592)−1.1 (−4.2, 2.0)*CE* clinical efficacy population, *CI* confidence interval, *MITT* modified intent-to-treat population, *MITTE* modified intent-to-treat efficacy population, *Vanc*/*Az* vancomycin plus aztreonam combination^a^Non-inferiority margin was set at −10% for both FOCUS and CANVAS trials^b^Treatment difference: cure rate ceftaroline − cure rate comparator group^c^Weighted treatment difference

The CANVAS Trials {#Sec6}
-----------------

The CANVAS (CeftAroliNe Versus vAncomycin in Skin and skin structure infections) 1 and 2 studies (NCT00424190 and NCT00423657, respectively) were multinational, multicenter, phase 3, double-masked, randomized, active comparator-controlled trials designed to evaluate the safety and efficacy of monotherapy with ceftaroline fosamil 600 mg IV every 12 h compared with a combination of vancomycin 1 g every 12 h plus aztreonam 1 g every 12 h IV for 5--14 days for the treatment of ABSSSI \[[@CR14], [@CR15], [@CR45], [@CR47]\] Dose adjustments for renal impairment by unblinded pharmacists were based on creatinine clearance and institutional guidelines.

The primary objective of the studies was to determine whether the clinical cure rate of ceftaroline fosamil was non-inferior to that of vancomycin plus aztreonam in the co-primary modified intent-to-treat (MITT) and CE populations at the TOC visit (8--15 days after completion of therapy). The non-inferiority margin was set at −10%. The MITT population included all subjects who received any amount of study drug according to their randomized treatment group. The CE population included subjects in the MITT population who demonstrated sufficient adherence to the protocol. Baseline characteristics and demographics were comparable between the two study arms in each study. The majority of participants were Caucasian males with a median age of 48 years diagnosed with cellulitis, major abscesses and infected wounds/ulcers. Of the 76% of subjects with a pathogen isolated, *S. aureus* was the most common; the proportion with MRSA was 40% in the ceftaroline group and 34% in the vancomycin plus aztreonam group. Aztreonam or a saline placebo was discontinued if a Gram-negative pathogen was not identified.

A priori-defined integrated analysis of the primary endpoints demonstrated non-inferiority of ceftaroline in the MITT and CE populations (Table [3](#Tab3){ref-type="table"}). In a planned secondary analysis of participants in the CE population with at least one pathogen isolated, clinical cure was achieved in 92.7% of the subjects in the ceftaroline treatment group compared with 94.4% receiving combination therapy (difference −1.7, 95% CI −4.9% to 1.6%) at TOC \[[@CR47]\]. In bacteremic subjects, cure rates were 84.6% (22 of 26 subjects) in the ceftaroline group compared to 100% (21 of 21 subjects) in the combination group (difference −15.4%, 95% CI −33.8% to 1.5%) \[[@CR47]\]. In particular, cure rates among subjects with *S.* *aureus* bacteremia were lower in the ceftaroline group (88.9%), but not statistically different from the combination group (100%) with, notably, twice as many subjects having *S. aureus* bacteremia in the ceftaroline group than in the combination group (18 vs. 9, respectively). At late follow-up (21--35 days after completion of therapy), clinical relapse rates were similar in the CE population: 1.1% and 0.9% in the ceftaroline and combination groups, respectively \[[@CR47]\]. Post hoc analysis requested by the FDA to evaluate clinical response with cessation of lesion spread and apyrexia on day 3 of study therapy was conducted in a subgroup of 797 subjects and showed a weighted difference of 7.7% (95% CI 1.3--14.0%) in favor of ceftaroline \[[@CR49]\].

Safety {#Sec7}
======

The safety profile of ceftaroline fosamil was evaluated in 1,740 participants and no unexpected safety concerns were identified \[[@CR5], [@CR48], [@CR50], [@CR51]\]. In the integrated FOCUS analysis, the most common adverse events occurring in greater than 2% of subjects receiving ceftaroline fosamil were diarrhea (4.2%), headache (3.4%), insomnia (3.1%) and phlebitis (2.8%) \[[@CR50]\]. In the integrated CANVAS analysis, the most common adverse events occurring in greater than 2% of subjects receiving ceftaroline fosamil were nausea (5.9%), headache (5.2%), diarrhea (4.9%), pruritus (3.5%), rash (3.2%), generalized pruritus (2.2%) and dizziness (2.0%) \[[@CR51]\]. Seroconversion to a positive direct anti-globulin (Coombs) test for the pooled data was higher in the ceftaroline group than comparator groups (10.7% vs. 4.4%, respectively), but was not associated with clinical hemolytic anemia \[[@CR48]\]. Potential allergic reactions occurred in 5.4% of those treated with ceftaroline fosamil compared with 8.5% of those treated with a comparator regimen, 0.2% and 0.4% of these reactions were assessed as severe, respectively \[[@CR48]\] Renal toxicity occurred in less than 2% and hepatic toxicity in less than 3% of those treated with ceftaroline fosamil. *Clostridium difficile*-associated diarrhea and seizures were reported, but were rare \[[@CR48]\].

Investigation of the effect of ceftaroline on human intestinal flora in adults who received infusions of ceftaroline fosamil IV every 12 h for 7 days revealed moderate decreases in the numbers of bifidobacteria and lactobacilli, with converse increases in the numbers of *Clostridium* spp., but minimal to no impact on *Bacteroides* spp. and aerobic bacteria \[[@CR52]\]. Toxin-producing strains of *C. difficile* were isolated from two asymptomatic subjects. No measurable fecal concentrations of ceftaroline were found, which may have helped to explain the limited ecological disruptions observed \[[@CR52]\]. At a dose of 1,500 mg, there was no clinically meaningful effect of ceftaroline fosamil on the QT interval \[[@CR53]\]. There is no evidence of teratogenicity in animal studies, but controlled studies in pregnant or lactating women have not been performed \[[@CR5]\]. Recently, isolated cases of eosinophilic pneumonia \[[@CR54]\] and neutropenia \[[@CR55]\] have been reported in patients receiving prolonged courses of ceftaroline; both events have been previously documented with cephalosporin use \[[@CR56]--[@CR60]\]. Overall, the cumulative data to date suggest that ceftaroline is well tolerated with a favorable safety profile, similar to the other drugs in the cephalosporin class.

Discussion {#Sec8}
==========

Current Role {#Sec9}
------------

There is a need for alternative antimicrobials that can safely and effectively treat common but serious bacterial infections, such as complicated skin and skin structure infections and CABP caused by emergent antibiotic-resistant pathogens. In 2005, there were over 14 million outpatient visits made in the USA for ABSSSIs \[[@CR61]\], which were among the most rapidly increasing reasons for hospitalizations between 1997 and 2007 \[[@CR62]--[@CR64]\], correlating with the rapid increase in the incidence of community-acquired MRSA infections between the mid-1990s and 2005 \[[@CR65]\]. There has been a great reliance on the glycopeptide, vancomycin, to treat MRSA, one of the most common pathogens associated with ABSSSIs, but resistant strains, including vancomycin-resistant *S. aureus* (VRSA) and VISA, have emerged \[[@CR66]\]. In addition, the rate of treatment failure is higher in strains with an MIC of 1 μg/mL or greater, which includes some strains that would be classified as susceptible using current guidelines \[[@CR67]\]. Vancomycin may also be inferior to β-lactam antibiotics for the treatment of methicillin-susceptible *S. aureus* bacteremia \[[@CR68]\]. Other FDA-approved antibiotics for the treatment of MRSA include linezolid, daptomycin, tigecycline and telavancin. There have been reports of *S. aureus* treatment failures with daptomycin and linezolid \[[@CR66]\] and toxicities associated with some of these options, such as myelosuppression myopathy and nephrotoxicity, are potentially limiting \[[@CR69]--[@CR71]\]. Ceftaroline is a safe and effective option for the parenteral treatment of skin and soft tissue infections, especially in cases where empiric MRSA and common Gram-negative coverage are desired.

Pneumonia, another common but potentially life-threatening infection, together with influenza, consistently rank among the top ten leading causes of death for all ages in the USA each year, and accounted for more than 1.2 million hospitalizations in 2006 \[[@CR72], [@CR73]\]. Antibiotic susceptibility of *S.* *pneumoniae*, the most common cause of CABP, has decreased in the USA over the past decade. In 2009, only 84.1%, 87.5% and 60.8% of surveyed *S.* *pneumoniae* isolates remained susceptible to penicillin, ceftriaxone and erythromycin, respectively \[[@CR74]\]. Ceftaroline is active against resistant Gram-positive pathogens and is a safe, well-tolerated alternative option for the parenteral treatment of CABP. Recently, the incidence of pneumonia due to community-associated MRSA has increased \[[@CR46]\]. Ceftaroline's major important advantage compared to other β-lactam antibiotics, such as ceftriaxone, is its activity against MRSA. Although ceftaroline fosamil is approved for the treatment of adults with ABSSSI caused by MRSA, there are no official data to support its use in the specific treatment of CABP caused by MRSA. An experimental pneumonia model demonstrated significantly decreased bacterial counts in the lungs of neutropenic mice, suggesting the possible usefulness of ceftaroline for the treatment of MRSA pneumonia \[[@CR6]\]. A trial of ceftaroline fosamil compared to ceftriaxone plus vancomycin in adults with CABP and at risk for MRSA infection is currently recruiting participants (NCT01645735) and will hopefully provide the clinical efficacy data needed to answer this question.

No pharmacoeconomic analyses on the cost effectiveness of ceftaroline compared to other agents are available. Using average wholesale prices in US dollars, the approximate cost for a 10-day course of ceftaroline (600 mg IV twice daily at \$119.96/day) in a patient with normal renal function seems comparable to the range of costs for a similar course of other antibiotics with MRSA activity, including vancomycin (1 g IV twice daily at \$9.40/day), linezolid (600 mg IV twice daily at \$288.8/day), daptomycin (500 mg IV once daily at \$362.51/day) and tigecycline (100 mg IV once daily or 50 mg IV twice daily at \$208.76/day) \[[@CR75]\]. Given the lack of clinical data in specific patient populations (such as those with MRSA pneumonia and bacteremia) and the demonstration of non-inferiority, rather than superiority, in phase 3 trials \[[@CR44], [@CR47]\], ceftaroline cannot currently be recommended over other alternative therapies for the treatment of CABP and ABSSSI, but should at least be considered in situations where concerns of resistance or toxicities may limit the use of other available drugs.

Future Considerations {#Sec10}
---------------------

Although ceftaroline has limited activity against resistant Gram-negative pathogens, time--kill experiments suggest extended coverage against resistant Enterobacteriaceae when combined with a β-lactamase inhibitor \[[@CR76]\]. In vitro and animal studies demonstrated that avibactam, a non-β-lactam β-lactamase inhibitor, has potent synergistic activity with ceftaroline \[[@CR29], [@CR77]--[@CR80]\]. Avibactam appears to inhibit ESBLs, including cephalosporinases and carbapenemases, and so may potentially enhance ceftaroline's spectrum of activity against Gram-negative bacteria. The development of a combination that offers such broad coverage is an exciting option for single-agent treatment of empiric or polymicrobial infections caused by multidrug-resistant Enterobacteriaceae and MRSA \[[@CR81]\]. Ceftobiprole, another new generation cephalosporin approved for use in some countries for the treatment of complicated skin and soft tissue infections (however, rejected by the FDA in 2009 and the European Medicines Agency in 2010) has extended Gram-positive activity similar to that of ceftaroline, and Gram-negative coverage similar to that of ceftazidime, but unlike ceftaroline--avibactam, ceftobiprole remains susceptible to hydrolysis by several ESBLs \[[@CR82], [@CR83]\]. Ceftaroline--avibactam was well tolerated in a phase 1 trial without demonstrating significant PK interaction when administered concomitantly \[[@CR84]\]. A phase 2 trial for the treatment of complicated urinary tract infections (NCT01281462) has been completed.

Animal models have been established to evaluate the in vivo efficacy of ceftaroline in the treatment of endocarditis, osteomyelitis and meningitis \[[@CR8], [@CR9], [@CR24], [@CR85], [@CR86]\]. Following a 4-day course of ceftaroline fosamil in a rabbit endocarditis model, ceftaroline demonstrated superior bactericidal activity against MRSA and heterogeneous VISA when compared to vancomycin and linezolid \[[@CR9]\]. Similarly, ceftaroline fosamil demonstrated significant bactericidal activity against MRSA and VISA, with a greater than 5 log~10~ colony-forming unit/g reduction of vegetation, which was comparable to that of daptomycin and superior to that of tigecycline \[[@CR24]\]. When compared to vancomycin and linezolid, ceftaroline demonstrated improved bacterial killing of vancomycin-sensitive and vancomycin-resistant *E. faecalis* in both time--kill experiments and a rabbit endocarditis model \[[@CR8]\]. Significant colony count reductions in infected joint and bone tissues were seen following a 4-day course of ceftaroline in an experimental rabbit model of acute MRSA osteomyelitis, which was comparable to that of linezolid and significantly better than that of vancomycin, indicating ceftaroline has good bone and joint penetration \[[@CR85]\]. Ceftaroline was superior to cefepime against *Klebsiella pneumoniae* in a rabbit meningitis model; the penetration of ceftaroline into inflamed and non-inflamed meninges was estimated to be 15% and 3%, respectively \[[@CR86]\].

Reports of off-label use of ceftaroline are also emerging. Prompt sterilization of blood following the addition of ceftaroline salvage therapy was documented in a review of six cases of persistent or recurrent MRSA bacteremia/endocarditis being treated with vancomycin or daptomycin \[[@CR87], [@CR88]\]. Interestingly, the five patients treated with a more aggressive regimen of ceftaroline 600 mg administered every 8 h all survived, while the patient who received ceftaroline every 12 h succumbed to other complications \[[@CR87]\]. A case report documented clearance of blood within 4 days of the addition of ceftaroline in a patient with endocarditis failing daptomycin therapy, and is supported by an in vitro PK/PD model, which showed that the addition of ceftaroline enhances daptomycin susceptibility \[[@CR88]\]. A similar PK/PD model showed that ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-susceptible and non-susceptible strains of MRSA, suggesting potency of this combination \[[@CR89]\]. Ceftaroline has also been used for the treatment of prosthetic joint infections \[[@CR90]\] and in a patient with osteomyelitis and endocarditis \[[@CR91]\]. Though clinical data on the use of ceftaroline for the treatment of infections other than CABP and ABSSSI are lacking, cumulatively, these in vivo animal studies and case reports provide early evidence that ceftaroline may potentially prove useful in the treatment of other serious bacterial infections.

Due to insufficient safety, PK and efficacy data, antibiotic options with MRSA activity in children are even more limited than in the adult population \[[@CR92]\]. Pediatric trials evaluating the safety and efficacy of ceftaroline for the treatment of CABP and complicated skin infections are currently recruiting patients (NCT01530763, NCT01669980 and NCT01400867). A cephalosporin with anti-MRSA activity may prove valuable, as β-lactam antibiotics are a popular choice for the treatment of infections in children, given their favorable safety profiles. As these and other post-marketing studies are underway, other areas to systematically address in the future include the effectiveness of ceftaroline in the treatment of immunocompromised patients, patients with septic shock and those with necrotizing fasciitis. Ongoing surveillance studies will also be necessary.

Conclusion {#Sec11}
==========

Ceftaroline fosamil is a well-tolerated and welcome addition to the available antibiotic options for the treatment of the increasing number of resistant Gram-positive and common Gram-negative infections. Clinical trials have demonstrated that the efficacy of ceftaroline fosamil is similar to that of comparator agents in the treatment of ABSSSI and CABP. Its lack of activity against resistant Gram-negative pathogens limits its current use as a monotherapeutic agent for the treatment of hospital-acquired infections, but with the addition of a β-lactamase inhibitor, such as avibactam, its activity may prove to be safely extended. Additional trials to further define the efficacy of ceftaroline in the treatment of other serious bacterial infections will be beneficial, as will safety and efficacy data in children.
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